𝐅𝐃𝐀 𝐀𝐜𝐜𝐞𝐩𝐭𝐬 𝐆𝐥𝐚𝐮𝐤𝐨𝐬'𝐬 𝐍𝐃𝐀 𝐟𝐨𝐫 𝐄𝐩𝐢𝐨𝐱𝐚: 𝐀 𝐍𝐞𝐰 𝐄𝐫𝐚 𝐢𝐧 𝐊𝐞𝐫𝐚𝐭𝐨𝐜𝐨𝐧𝐮𝐬 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭
👁 The acceptance of Glaukos Corporation’s NDA for Epioxa marks a significant advancement in treating keratoconus, a condition where the cornea weakens and bulges, causing vision distortion. Epioxa offers a faster, non-invasive treatment option compared to traditional corneal cross-linking therapies, which require epithelium removal.
🏥 In the UK, patients have benefited from local access to corneal cross-linking at Musgrove Park Hospital, which has improved their vision and stabilized the condition. This procedure has a 95% success rate, providing hope for many patients with this debilitating disease.